The stock of Kronos Bio Inc (KRON) has seen a 28.96% increase in the past week, with a 21.94% gain in the past month, and a -9.50% decrease in the past quarter. The volatility ratio for the week is 1.24%, and the volatility levels for the past 30 days are at 1.66% for KRON. The simple moving average for the last 20 days is 23.55% for KRON stock, with a simple moving average of -5.26% for the last 200 days.
Is It Worth Investing in Kronos Bio Inc (NASDAQ: KRON) Right Now?
The 36-month beta value for KRON is also noteworthy at 1.64. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for KRON is 39.42M, and at present, short sellers hold a 1.39% of that float. The average trading volume of KRON on June 05, 2025 was 535.17K shares.
KRON) stock’s latest price update
The stock price of Kronos Bio Inc (NASDAQ: KRON) has surged by 28.33 when compared to previous closing price of 0.67, but the company has seen a 28.96% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-05-04 that NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kronos Bio, Inc. (NasdaqGS: KRON) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Kronos will receive $0.57 in cash per share plus one non-tradeable contingent value right. KSF is seeking to determine whether this consideration and the process that le.
Analysts’ Opinion of KRON
Piper Sandler, on the other hand, stated in their research note that they expect to see KRON reach a price target of $1, previously predicting the price at $6. The rating they have provided for KRON stocks is “Neutral” according to the report published on November 14th, 2024.
Berenberg gave a rating of “Buy” to KRON, setting the target price at $12 in the report published on September 14th of the previous year.
KRON Trading at 12.28% from the 50-Day Moving Average
After a stumble in the market that brought KRON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.88% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at KRON starting from BISCHOFBERGER NORBERT W, who purchase 410,848 shares at the price of $1.17 back on Jun 27 ’24. After this action, BISCHOFBERGER NORBERT W now owns 10,597,468 shares of Kronos Bio Inc, valued at $478,843 using the latest closing price.
BISCHOFBERGER NORBERT W, the PRESIDENT & CEO of Kronos Bio Inc, purchase 204,670 shares at $1.25 during a trade that took place back on Jun 28 ’24, which means that BISCHOFBERGER NORBERT W is holding 10,802,138 shares at $254,957 based on the most recent closing price.
Stock Fundamentals for KRON
Current profitability levels for the company are sitting at:
- -7.65 for the present operating margin
- 0.71 for the gross margin
The net margin for Kronos Bio Inc stands at -7.02. The total capital return value is set at -0.7. Equity return is now at value -59.49, with -44.30 for asset returns.
Based on Kronos Bio Inc (KRON), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -2.26. The debt to equity ratio resting at 0.3. The interest coverage ratio of the stock is -65.25.
Currently, EBITDA for the company is -61.72 million with net debt to EBITDA at 1.29. When we switch over and look at the enterprise to sales, we see a ratio of -1.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.93.
Conclusion
In summary, Kronos Bio Inc (KRON) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
